SecBot SecBot
SECBOTREPLAY Home › Report › HCM

HCM · HUTCHMED announced positive pivotal Phase II results for fanregratinib…

HUTCHMED (China) Limited · PRESS-RELEASE filed Jun 24, 2026 at 20:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 24, 2026 at 20:00 ET

HUTCHMED announced positive pivotal Phase II results for fanregratinib in FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma (ICC), with an IRC-assessed ORR of 42.5% and median OS of 16.6 months. The NDA has been accepted and granted priority review by China's NMPA, positioning fanregratinib as a potential new treatment option in a targeted ICC population.

  • Pivotal Phase II study met primary endpoint with IRC-assessed ORR of 42.5% (95% CI: 30.0%–53.6%) in advanced ICC patients with FGFR2 fusions/rearrangements.
  • Median progression-free survival (PFS) was 6.9 months; median overall survival (OS) was 16.6 months.
  • NDA for fanregratinib in this indication accepted and granted priority review by China's NMPA in December 2025.
  • Drug-related Grade 3+ adverse events occurred in 48.3% of patients; treatment discontinuation due to AEs was only 2.2% with no treatment-related deaths.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access